A 65-year-old patient with stage III NSCLC comes to your clinic to discuss concurrent chemoradiotherapy. She has a history of ischemic heart disease, and 4 years ago an angiogram demonstrated […] Read more
Hippocampal-Sparing Brain Irradiation: The Future of Brain Metastases Treatment and Prevention?
Lizza Hendriks+more
Brain metastases (BMs) are frequently diagnosed in patients with SCLC and NSCLC, although the incidence is highest in SCLC.1 ,2 ,3 BMs are a negative prognostic factor and are associated […] Read more
Prophylactic Radiotherapy: A Case for Patients at High Risk of Brain Metastases
Oscar Arrieta+more
Prophylactic radiotherapy for the prevention of brain metastases (Table 1) has not been considered a standard practice outside of limited stage SCLC, particularly amid the surge and approval of novel […] Read more
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Con Side
Annemarie Fernandes Shepherd+more
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Pro Side
Kristin A. HigginsThe controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeti... Read more
Deeper Dive Toxicity of Lung SBRT and Concurrent Immunotherapy Combinations: What We Know and What We Still Need to Learn
Sibo Tian, MD+more
In Reference To: Tian S, Switchenko JM, Buchwald ZS, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108(1):304-313. Read more
The Dandelion Dilemma of Brain Metastases: Treating the Whole Lawn or the Weeds Separately
Hina Saeed, MD+more
Approximately, 40% to 60% of patients with small cell lung cancer (SCLC) develop brain metastases (BMs),1 ,2 ,3 and fewer than 15% survive beyond 2 years.4 ,5 Whereas upfront stereotactic […] Read more
PET vs. CT in Lung Cancer Surveillance: The ‘Pro’ Side from the Nuclear Medicine Perspective
Asha Kandathil, MDA significant proportion of patients with stage I to III NSCLC or SCLC will have locoregional or distant metastases following curative-intent therapy. Studies have reported local recurrence rates of 22% […] Read more
Patient Perspectives on CT and PET Scans: Imaging Technology Provides Different Benefits, Drawbacks for Each Individual Patient
Ivy Elkins, MBA+more
For patients with metastatic lung cancer, frequent scans are a stark reality of living with cancer. Although most scans happen every 3 months, some clinical trials require scans more often […] Read more
FDG PET–CT Versus CT for Lung Cancer Surveillance: The "Con" Side
Palmi Shah, MDLung cancer remains the leading cause of cancer-related deaths.1 Advances in early detection of lung cancer following the implementation of screening programs and the availability of newer therapies have increased […] Read more